Agenus (Formerly known as Antigenics Inc. - Lexington, MA) and VaxLogic, LLC Execute QS-21 Stimulon Adjuvant Licensing Agreement for Addiction, Allergy and Respiratory Vaccines
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN) today announced that it is has entered into a non-exclusive license agreement with VaxLogic, LLC, a subsidiary of PharmLogic LLC, for the use of QS-21 Stimulon®1 adjuvant in the development of select addiction, allergy and respiratory disease vaccine candidates.
Help employers find you! Check out all the jobs and post your resume.